Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | PRKCA | P17252 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884741 | 0.88 | MAPT (0.71) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13295527 | 0.87 | MAPT (0.69) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL10613692 | 0.86 | MAPT (0.64) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13884730 | 0.85 | MEN1 (0.67) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13893449 | 0.85 | MAPT (0.67) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13178023 | 0.83 | MAPT (0.64) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13473966 | 0.81 | MAPT (0.71) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL11882893 | 0.81 | NPC1 (0.67) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL30749688 | 0.81 | MAPT (0.61) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13370284 | 0.81 | MEN1 (1.00) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63223064-A | — | — | None | — | — | JP | disclosed |
| EP-1624028-B1 | Anthraquinone colorant compounds | XEROX CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7901496-B2 | Phase change inks | XEROX CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7683192-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-7622580-B2 | Colorant compounds | XEROX CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1621592-B1 | Phase change inks | XEROX CORP (US) | 2009-10-07 | — | — | EP | disclosed |
| US-7211131-B2 | Phase change inks | XEROX CORPORATION (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060032397-A1 | Hot melts; for ink jet/piezoelectric printing | XEROX CORPORATION | 2006-02-16 | — | — | US | disclosed |
| US-20060036095-A1 | Colorant compounds | XEROX CORPORATION | 2006-02-16 | — | — | US | disclosed |
| EP-1626072-A1 | Phase change inks | Xerox Corporation (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1626071-A1 | Anthrapyridone colorant compounds | Xerox Corporation (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1624028-A1 | Anthraquinone colorant compounds | Xerox Corporation (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20060025616-A1 | Colorant compounds | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060021547-A1 | Phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1621592-A1 | Phase change inks | Xerox Corporation (US) | 2006-02-01 | — | — | EP | disclosed |
| JP-S63223064-A | BLUE COLORING MATTER FOR USE IN FILTER | MITSUI TOATSU CHEM INC | 1988-09-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036095-A1 | Colorant compounds | RB1, NDUFS6, PRMT6 | NPC1 1476/4885RAB9A 610/4885MAPT 1546/4885 |
| US-20060021547-A1 | Phase change inks | NR4A3, RB1, CDK3 | NPC1 2275/4885RAB9A 1158/4885MAPT 3109/4885 |
| US-20060025616-A1 | Colorant compounds | NR4A3, NR0B2, NR2E3 | NPC1 2556/4885RAB9A 2324/4885MAPT 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.